Exchange: NASDAQ·Updated 07:30 PM EDT
About LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.